

Saskatchewan Immunization Manual Amendments July 2025

Instructions: Please remove and discard the corresponding pages in each chapter section as noted below and insert these amended pages in the corresponding chapter section.

Chapter 7 Immunization of Special Populations

- **P. 13 Section 2.14 Sickle Cell Disease**
 - **New paragraph added:**
 - If they receive blood/blood products for disease management or treatment, ensure the client's risk factors are updated in Panorama (e.g., Chronic Medical Condition – Bleeding Disorders) and appropriate HB vaccine series is provided.
- **P. 41 App 7.6 Publicly Funded Immunization Schedule for Adult Post-Hematopoietic Stem Cell Transplant Recipients**
 - **New footnote #16:** Confirmation of VZV seropositivity post-Var series is recommended before providing RZV series.
- **P. 43 Appendix 7.8 Publicly Funded Immigrant and Refugee Immunization and Serology Recommendations**
 - Update HC country list link added to footnote #3: Refer to the CDA Foundation. Hepatitis C – [Country name]. Lafayette, CO: CDA Foundation, 2025. Available from <https://cdafound.org/polaris/database-query/> (Accessed July 7, 2025).
- **P. 44 App 7.9 Publicly Funded Immunization Schedule for Adult Solid Organ Pre-Transplant Candidates**
 - **New footnote #14:** Confirmation of VZV seropositivity post-Var series is recommended before providing RZV series.
- **P. 45 App 7.10 Publicly Funded Immunization Schedule for Adult Solid Organ Post-Transplant Recipients**
 - Added to footnote #12: VZV titre may be recommended before providing RZV series.

Chapter 8 Administration of Biological Products

- **TOR second page**
 - **New!** Appendix 8.5: Mass Immunization Clinic Infection Control Recommendations
 - **New!** Appendix 8.6: Immunization Clinic Supply Recommendations
- **P. 37 **New!** Appendix 8.5: Mass Immunization Clinic Infection Control Recommendations**
 - This document has been removed from the Seasonal Influenza Immunization Policy to be permanently placed in Ch. 8.
- **P. 38 **New!** Appendix 8.6: Immunization Clinic Supply Recommendations**
 - This document has been removed from the Seasonal Influenza Immunization Policy to be permanently placed in Ch. 8.

Chapter 10 Biological Product

- **TOC p. 1**
 - **New!** Avian Influenza – Human H5N1 vaccine AREPANRIX™
- **New vaccine content! Avian Influenza – Human H5N1 vaccine AREPANRIX™**
 - Eligibility is not included in the content.
 - Preparation instructions on page 2.
- **Herpes zoster vaccine (SHINGRIX™) (page 1 of 2)**
 - Added after directives to follow varicella immunization: Confirmation of VZV seropositivity post-Var series is recommended.
- **Smallpox/mpox**
 - Latest NACI statement now reference 1.
 - Pre-exposure Prophylaxis (PrEP) amendments:
 - Personnel who work in research laboratory settings and who are at high risk of occupational exposure to replicating orthopoxviruses that pose a risk to human health

Saskatchewan Immunization Manual Amendments July 2025

- Additional doses may be offered to personnel working in a research laboratory setting who remain at risk of occupational exposure, with a minimal interval of every 2 years.
- Travelers to an area with ongoing community transmission of MPXV clade I (as per PHAC's Travel health notices, [Mpox: Advice for travellers](#)) and anticipate either prolonged close contact (such as sharing accommodation) with people who reside in that area or sexual contact with people who reside in, or spend extended time in, that area.
- Immunization may be considered on an individual basis [for non-international travelling] healthcare workers based on a high risk of frequent exposure.

Chapter 14 Appendices

- **P. 21 App. 14.3 Immunization Fact Sheets**
 - Smallpox/mpox vaccine fact sheet updated July 2025